ThromboGenics to Present the Industry Pipeline of DME Treatments at Upcoming European Society of Ophthalmology Congress, Barcelona, Spain

LEUVEN, Belgium, June 8, 2017 /PRNewswire/ --

ThromboGenics NV (Euronext Brussels: THR), a biotechnology company developing novel treatments for diabetic eye disease, announced today that it will give a presentation at the European Society of Ophthalmology Congress, which is held from June 10-13 in Barcelona, Spain.

The presentation "The industry pipeline for diabetic macular edema (DME), what does it hold?" will be given by Jean Feyen, PhD, Head of R&D at ThromboGenics. In his presentation, Dr Feyen will provide an overview of the current standard of care for DME, the unmet medical need, future treatments for DME currently under development and delivery mechanisms.

ThromboGenics has a pipeline of disease modifying drug candidates targeting the key segments of the diabetic eye disease market: non-proliferative diabetic retinopathy, proliferative diabetic retinopathy, with or without DME.

Dr Feyen's presentation will take place from 11:00 - 11:15am CET, Tuesday 13 June.

"We arehonoredwith thisopportunity tojoin thisprestigiousmeetingofthe European Society of Ophthalmology," said Dr.Patrik De Haes, MD, CEO of ThromboGenicsNV."There is a clear unmet medical need for improved treatment options for diabetic eye disease in general, and diabetic macular edema specifically.Our current development pipelineis focused on addressing this need and weare currentlydeveloping4newdisease modifyingtherapies,eachwiththe potential to improve on the current standard of care foranumber ofdiabetic eye disease indications."

About ThromboGenics 

ThromboGenics is a biopharmaceutical company focused on developing innovative treatments for diabetic eye disease. The company's pipeline of disease modifying drug candidates is targeting the key segments of the diabetic eye disease market.

ThromboGenics is conducting the CIRCLE study, a Phase II clinical trial evaluating multiple doses of THR-409 (ocriplasmin) to induce a total Posterior Vitreous Detachment in patients with Non-Proliferative Diabetic Retinopath (NPDR).

ThromboGenics is conducting a Phase II clinical study evaluating THR- 317, a PlGF inhibitor for the treatment of diabetic macular edema, as a stand-alone or as a combination therapy with anti-VEGF treatments. In addition, THR-149, a plasma kallikrein inhibitor, which has resulted from research collaboration with Bicycle Therapeutics, and THR-687, an integrin antagonist, which was in-licensed from Galapagos, are in late stage pre-clinical development.

ThromboGenics pioneered a new drug category of pharmacological vitreolysis with JETREA® (ocriplasmin) which is now approved for the treatment of symptomatic vitreomacular traction in 54 countries worldwide. ThromboGenics is commercializing JETREA® via its subsidiary ThromboGenics, Inc. in the US. Novartis commercializes JETREA® outside the United States.

ThromboGenics is headquartered in Leuven, Belgium, and is listed on the NYSE Euronext Brussels exchange under the symbol THR.

More information is available at www.thrombogenics.com

For further information please contact:
ThromboGenics
Wouter Piepers
Global Head of Corporate Communications & IR
+32-16-75-13-10 / +32-478-33-56-32
wouter.piepers@thrombogenics.com

Citigate Dewe Rogerson
David Dible/Sylvie Berrebi
Tel: +44-20-7282-9571
david.dible@citigatedr.co.uk
sylvie.berrebi@citigatedr.co.uk

Important information about forward-looking statements
Certain statements in this press release may be considered"forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report.

This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of ThromboGenics in any jurisdiction. No securities of ThromboGenics may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.

SOURCE ThromboGenics